These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30954027)

  • 1. Phenotypic diversity and glucocorticoid sensitivity in patients with familial partial lipodystrophy type 2.
    Resende ATP; Martins CS; Bueno AC; Moreira AC; Foss-Freitas MC; de Castro M
    Clin Endocrinol (Oxf); 2019 Jul; 91(1):94-103. PubMed ID: 30954027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irisin levels in LMNA-associated partial lipodystrophies.
    Bensmaïne F; Benomar K; Espiard S; Vahe C; Le Mapihan K; Lion G; Lemdani M; Chazard E; Ernst O; Vigouroux C; Pigny P; Vantyghem MC
    Diabetes Metab; 2019 Jan; 45(1):67-75. PubMed ID: 30165155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FPLD2 LMNA mutation R482W dysregulates iPSC-derived adipocyte function and lipid metabolism.
    Friesen M; Cowan CA
    Biochem Biophys Res Commun; 2018 Jan; 495(1):254-260. PubMed ID: 29108996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction.
    Bidault G; Garcia M; Vantyghem MC; Ducluzeau PH; Morichon R; Thiyagarajah K; Moritz S; Capeau J; Vigouroux C; Béréziat V
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2162-71. PubMed ID: 23846499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Value of Anthropometric Measurements for Familial Partial Lipodystrophy, Dunnigan Variety.
    Vasandani C; Li X; Sekizkardes H; Adams-Huet B; Brown RJ; Garg A
    J Clin Endocrinol Metab; 2020 Jul; 105(7):2132-41. PubMed ID: 32193531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional Body Fat Changes and Metabolic Complications in Children With Dunnigan Lipodystrophy-Causing LMNA Variants.
    Patni N; Li X; Adams-Huet B; Vasandani C; Gomez-Diaz RA; Garg A
    J Clin Endocrinol Metab; 2019 Apr; 104(4):1099-1108. PubMed ID: 30418556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Describing the natural history of clinical, biochemical and radiological outcomes of children with familial partial lipodystrophy type 2 (FPLD2) from the United Kingdom: A retrospective case series.
    Zhong ZX; Harris J; Wilber E; Gorman S; Savage DB; O'Rahilly S; Stears A; Williams RM
    Clin Endocrinol (Oxf); 2022 Dec; 97(6):755-762. PubMed ID: 35920656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycystic ovary syndrome in familial partial lipodystrophy type 2 (FPLD2): basic and clinical aspects.
    Gambineri A; Zanotti L
    Nucleus; 2018; 9(1):392-397. PubMed ID: 30131000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of LMNA in adipose: a novel mouse model of lipodystrophy based on the Dunnigan-type familial partial lipodystrophy mutation.
    Wojtanik KM; Edgemon K; Viswanadha S; Lindsey B; Haluzik M; Chen W; Poy G; Reitman M; Londos C
    J Lipid Res; 2009 Jun; 50(6):1068-79. PubMed ID: 19201734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiazolidinedione response in familial lipodystrophy patients with LMNA mutations: a case series.
    Luedtke A; Boschmann M; Colpe C; Engeli S; Adams F; Birkenfeld AL; Haufe S; Rahn G; Luft FC; Schmidt HH; Jordan J
    Horm Metab Res; 2012 Apr; 44(4):306-11. PubMed ID: 22274718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A recurrent familial partial lipodystrophy due to a monoallelic or biallelic LMNA founder variant highlights the multifaceted cardiac manifestations of metabolic laminopathies.
    Treiber G; Flaus Furmaniuk A; Guilleux A; Medjane S; Bonfanti O; Schneebeli S; Bernard C; Le-Moullec N; Bakiri F; Pholsena M; Rollot O; Vatier C; Jarlet E; Jéru I; Lascols O; Darcel F; Domun B; Venault A; Venault S; Jacquemont ML; Doray B; Maiza JC; Cogne M; Vigouroux C; Nobécourt E
    Eur J Endocrinol; 2021 Aug; 185(4):453-462. PubMed ID: 34292171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel phenotypic expression associated with a new mutation in LMNA gene, characterized by partial lipodystrophy, insulin resistance, aortic stenosis and hypertrophic cardiomyopathy.
    Araújo-Vilar D; Lado-Abeal J; Palos-Paz F; Lattanzi G; Bandín MA; Bellido D; Domínguez-Gerpe L; Calvo C; Pérez O; Ramazanova A; Martínez-Sánchez N; Victoria B; Costa-Freitas AT
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):61-8. PubMed ID: 18031308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C.
    Wong SP; Huda M; English P; Bargiota A; Wilding JP; Johnson A; Corrall R; Pinkney JH
    Diabetologia; 2005 Dec; 48(12):2641-9. PubMed ID: 16320084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lipodystrophic hotspot lamin A p.R482W mutation deregulates the mesodermal inducer T/Brachyury and early vascular differentiation gene networks.
    Briand N; Guénantin AC; Jeziorowska D; Shah A; Mantecon M; Capel E; Garcia M; Oldenburg A; Paulsen J; Hulot JS; Vigouroux C; Collas P
    Hum Mol Genet; 2018 Apr; 27(8):1447-1459. PubMed ID: 29438482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adipocyte-Specific Deletion of Lamin A/C Largely Models Human Familial Partial Lipodystrophy Type 2.
    Corsa CAS; Walsh CM; Bagchi DP; Foss Freitas MC; Li Z; Hardij J; Granger K; Mori H; Schill RL; Lewis KT; Maung JN; Azaria RD; Rothberg AE; Oral EA; MacDougald OA
    Diabetes; 2021 Sep; 70(9):1970-1984. PubMed ID: 34088712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The p.R482W substitution in A-type lamins deregulates SREBP1 activity in Dunnigan-type familial partial lipodystrophy.
    Vadrot N; Duband-Goulet I; Cabet E; Attanda W; Barateau A; Vicart P; Gerbal F; Briand N; Vigouroux C; Oldenburg AR; Lund EG; Collas P; Buendia B
    Hum Mol Genet; 2015 Apr; 24(7):2096-109. PubMed ID: 25524705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Dietary Intake, Leisure-Time Physical Activity, and Metabolic Profile in Women with Mutation in the LMNA Gene.
    Monteiro L; Foss-Freitas MC; Navarro A; Pereira F; Coeli F; Carneseca E; Júnior RM; Foss M
    J Am Coll Nutr; 2017; 36(4):248-252. PubMed ID: 28443701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fertility and obstetrical complications in women with LMNA-related familial partial lipodystrophy.
    Vantyghem MC; Vincent-Desplanques D; Defrance-Faivre F; Capeau J; Fermon C; Valat AS; Lascols O; Hecart AC; Pigny P; Delemer B; Vigouroux C; Wemeau JL
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2223-9. PubMed ID: 18364375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Familial partial lipodystrophy (Dunnigan syndrome) due to LMNA gene mutation: The first description of its clinical case in Russia].
    Sorkina EL; Kalashnikova MF; Melnichenko GA; Tyulpakov AN
    Ter Arkh; 2015; 87(3):83-87. PubMed ID: 26027246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deregulation of Fragile X-related protein 1 by the lipodystrophic lamin A p.R482W mutation elicits a myogenic gene expression program in preadipocytes.
    Oldenburg AR; Delbarre E; Thiede B; Vigouroux C; Collas P
    Hum Mol Genet; 2014 Mar; 23(5):1151-62. PubMed ID: 24108105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.